Abstract:The 2016 Lasker-DeBakey Clinical Medical Research Award was given to three scientists working on different stages of the translational sciences on bringing a high efficacious therapy against hepatitis C virus (HCV) infection to a reality. An effective treatment of HCV chronic infection was developed, by a team led by Michael Sofia, using a prodrug approach and the drug PSI-7977 or Sofosbuvir was approved in 2013 less than 28 years after the initial discovery of HCV. This breakthrough was enabled by the availability of the subgenomic HCV replication system, developed by Charles Rice and Ralf Bartenschlager in 1999. The clinically proven Sofosbuvir with remarkable safety and efficacy was designed to enter the hepatocytes readily and to be processed upon cell entry to a triphosphate derivative, becoming a fully activated competitive and high affinity inhibitor for the HCV NS5B, an RNA-dependent RNA polymerase. While hepatitis diseases as a whole still pose a major public health issue globally, according to a WHO report (WHO reference number: WHO/HIV/2016.06, Global health sector strategy on viral hepatitis, 20162021) (http://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/)) the past few years has witnessed a major breakthrough in the antiviral treatment therapy for hepatitis C. HCV is one of the two viruses, B and C, for causing significant disease burden globally due to the progression to liver cirrhosis or cancers. It culminated recently with Charles Rice and Ralf Bartenschlager, together with Michael Sofia, winning the 2016 Lasker-DeBakey Clinical Medical Research Award. The discoveries of Rice and Bartenschlager led to the development of functional HCV replicons. Sofia harnessed the power of this newly available tool of “live HCV in the lab” for identification and improvement of anti-HCV drugs, leading to the development of a novel molecule using a prodrug approach, now known as Sofosbuvir (PSI-7977). The milestones in HCV virology and in antiviral drug development are illustrated in Figure 1. The 2016 Lasker Award represents the second time of Lasker Award series recognizing achievement in the HCV field with the 2000 Lasker award on the initial discovery of HCV and the development of screening methods that reduced the risk of its transmission.

The Discovery and Research Progress of Hepatitis C Virus: The Enlightenment of The Nobel Prize in Physiology or Medicine of 2020

From Discovery to Cure, A Great Journey of the Hepatitis C Virus Study

Breakthroughs in hepatitis C research: from discovery to cure

The Scientific Progress and Prospects of Hepatitis C Research from 2013 to 2022.

From non-A, non-B hepatitis to hepatitis C virus cure

The 2016 Lasker-DeBakey Clinical Medical Research Award: Innovative Hepatitis C Virus (HCV) Replicons Leading to Drug Development for Hepatitis C Cure

Hepatitis Virus and Hepatocellular Carcinoma: Recent Advances

HCV virology and diagnosis

The Laboratory Diagnosis of Viral Hepatitis in the Era of Antiviral Therapy

Research Progress of Hepatitis C in 2018

Scotomas in molecular virology and epidemiology of hepatitis C virus

Recent Advance in Antiviral Drugs for Hepatitis C.

Advance in the Research of the Nonstructural Protein NS2 of Hepatitis C Virus

An Insight into Hepatitis C Virus: In Search of Promising Drug Targets

An insight into the molecular characteristics of hepatitis C virus for clinicians

Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies

Current advances in Hepatitis C diagnostics

Analysis of articles on hepatitis C by scientific mapping: 1989-2022

Chronicles of HBV and the Road to HBV Cure

The immune pathogenesis progress of hepatitis C virus

Innate Detection of Hepatitis B and C Virus and Viral Inhibition of the Response